FDA Clears GLP-1 Drugs on Suicide Risk: What the 2.2 Million-Patient Study Found

The Concern

In July 2023, Iceland's medicine agency flagged a disproportionate number of reports of suicidal thoughts and self-injury in people taking liraglutide and semaglutide. This triggered investigations by the European Medicines Agency, Health Canada, and the FDA. Meanwhile, the prescribing information for GLP-1 medications approved for weight loss (Saxenda, Wegovy, Zepbound) already included warnings about suicidal behavior and ideation — a legacy from earlier weight-loss drugs that had been pulled from the market for psychiatric safety concerns.

The concern was particularly relevant for potential addiction applications because people with substance use disorders have significantly elevated rates of depression, anxiety, PTSD, and suicidal ideation. If GLP-1 medications increased psychiatric risk, they could be especially dangerous in the very population that might benefit most from their anti-craving effects.

What the FDA Found

The FDA conducted a retrospective cohort study using the Sentinel System — a massive healthcare claims database — comparing the risk of intentional self-harm between new users of GLP-1 medications and new users of SGLT2 inhibitors (another class of diabetes medication). The study included 2,243,138 patients: 1,161,983 on a GLP-1 and 1,081,155 on an SGLT2 inhibitor.

The results were definitive: no increased risk of suicidal behavior or ideation was found among GLP-1 users. No increased risk of depression, anxiety, irritability, or psychosis either. Based on these findings, the FDA issued an updated Drug Safety Communication on January 13, 2026, and took the unusual step of requesting that manufacturers remove the suicide-related warning language from their labels.

The NIH Study: Lower Risk

A separate NIH-led study, published in September 2025 and covered by NIH Research Matters, went further. Analyzing electronic health records of more than 240,000 patients, researchers found that semaglutide use was associated with a lower risk of suicidal ideation compared to other diabetes and obesity medications — not just neutral, but potentially protective.

Dr. Nora Volkow, Director of NIDA and a co-author, stated that the findings suggest semaglutide can be safe for those with mental health conditions — a crucial reassurance given that people with substance use disorders almost universally have comorbid mental health diagnoses.

What This Means for Addiction Treatment

The clearance of suicide risk is not just a regulatory footnote. It removes a significant barrier — both real and perceived — to using GLP-1 medications in people with addiction. Clinicians who might have hesitated to prescribe these drugs to patients with depression, PTSD, or suicidal history now have large-scale safety data supporting their use.

This is especially important because the overlap between addiction and psychiatric conditions is enormous. An estimated 50% of people with substance use disorders have a co-occurring mental health condition. Any medication being considered for addiction treatment must be safe in this population, and the FDA's 2.2-million-patient analysis provides that assurance.